Overview: Desmin Immunohistochemistry TestIntroduction: The Desmin Immunohistochemistry Test detects desmin protein to diagnose muscle tumors, causing pain or swelling. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected soft tissue sarcomas, such as rhabdomyosarcoma.
Other Names: Desmin IHC Assay, Muscle Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Desmin testing began in the 1980s with sarcoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects desmin to diagnose muscle tumors, guides treatment, and evaluates patients with pain or swelling.
Test Parameters: 1. Desmin Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of pain, swelling, or muscle masses.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document pain, swelling, muscle masses, or family history of sarcomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect desmin in muscle tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for sarcoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive desmin staining suggests muscle tumors (e.g., rhabdomyosarcoma, leiomyosarcoma), guiding surgery or chemotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an oncologist or orthopedic oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Myogenin IHC, SMA IHC, or MRI to confirm muscle tumor diagnosis.
Test Limitations: Not specific to one sarcoma type; other tumors may express desmin. Clinical correlation is needed.
References: WHO Soft Tissue Tumor Guidelines, 2023; American Journal of Surgical Pathology, Miettinen M, 2022.
